Here are the 10-Q quarterly reports from HI-GREAT GROUP HLDG CO (HIGR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HIGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIGR filings page.
Hi-Great Group Holding Co (HIGR) reported that for the six months ended June 30, 2026 it generated sales of $20,210, modestly higher than $19,018 a year earlier, but remained unprofitable with a net loss of $20,167, improved from a $35,982 loss in the prior-year period.
Total assets were only $15,836 against total liabilities of $283,939, leaving a stockholders’ deficit of $268,104 and an accumulated deficit of $1,000,169. Cash was $923 at June 30, 2026, and the company disclosed substantial related-party payables, including $173,764 of accrued royalty to SellaCare, Inc. Management describes Hi-Great as a development stage enterprise focused on agritourism, SellaCare herbal supplements, and a KRAS gene licensing strategy, and states there is substantial doubt about its ability to continue as a going concern without additional financing.
Hi-Great Group Holding Company reports unaudited results for the quarter ended March 31, 2026. The development-stage company generated sales of $13,255, up from $8,883 a year earlier, and reduced its net loss to $7,830 from $18,938 as gross profit improved.
Total assets were $22,105, almost entirely cash and inventory, against total liabilities of $277,871, leaving a stockholders’ deficit of $255,766 and an accumulated deficit of $987,832. Operations provided $4,570 of cash in the quarter, but the company’s auditor highlights substantial doubt about its ability to continue as a going concern because it has not yet established revenue sufficient to cover operating costs and remains dependent on external financing.
The business focuses on agritourism, herbal supplements, and an exclusive global licensing effort related to the KRAS gene, with significant ongoing royalty and lease arrangements involving related parties.
Hi-Great Group Holding Company reported financial results for the period ended September 30, 2025, reflecting development-stage operations with modest revenue and ongoing losses. For the nine months, sales were $34,518 compared with $55,700 a year earlier, producing gross profit of $13,854. Operating expenses of $58,559 led to a net loss of $44,268, close to the prior-year loss of $43,006.
At September 30, 2025, cash totaled $7,986 and total assets were $72,286. Liabilities were $277,282, including $171,037 of accrued licensing royalties owed to a related party, resulting in stockholders’ deficit of $204,996 and an accumulated deficit of $937,062. Management notes a going concern uncertainty, stating the company has not yet generated revenues sufficient to cover operating costs and remains dependent on external financing.
The company remains a development-stage business involved in agritourism and selling SellaCare-branded herbal supplements under a worldwide related-party license, while pursuing an exclusive global licensing agreement related to the KRAS gene and planning expansion into cosmetics. Shares outstanding were 102,500,000 as of September 30, 2025, after equity grants to an officer and a service provider. Management concluded disclosure controls and procedures were not effective, though it reported no material changes in internal control during the quarter.